Notable Earnings: Infosys Ltd. (INFY), Biogen Inc. (BIIB), ImmunoGen, Inc. (IMGN)

Infosys Ltd. (INFY) shares are down $2.92, or 8.32%, to $32.05 in pre-market trading Friday after the company reported its fourth-quarter earnings results.

India’s second-largest software-services provider reported earnings of 27.10 rupees ($0.42) per share on revenues of 134.11 billion rupees ($2.10 billion), up 4.2% from a year ago. Analysts were expecting EPS of 27.63 rupees ($0.43) on revenues of $139.06 billion rupees ($2.19 billion). For the current quarter, net income was 3.09 billion rupees, compared with net income of 2.99 billion rupees in the first quarter of 2014.

For FY/16, INFY provided revenue projection of 10% – 12% in constant currency terms, compared to the consensus revenue estimate of 601.44 billion rupees.

On valuation measures, Infosys Ltd. ADS shares, which currently have an average 3-month trading volume of 2.63 million shares, trade at a trailing-12 P/E of 19.98, a forward P/E of 18.70 and a P/E to growth ratio of 1.47. The median Wall Street price target on the name is $37.76 with a high target of $44.74. Currently ticker boasts 25 ‘Buy’ endorsements, compared to 14 ’Holds’ and 5 ‘Sell’.

Profitability-wise, INFY has a t-12 profit and operating margin of 23.16% and 26.64%, respectively. The name currently prints a one year return of 36.51% and a year-to-date return of 11.13%.

The chart below shows where the equity has traded over the last 52 weeks.

Biogen Inc. (BIIB) reported first quarter EPS of $3.82 before the opening bell Friday, compared to the consensus estimate of $3.91. Revenues increased 20% from last year to $2.56 billion. Analysts expected revenues of $2.66 billion. First-quarter profit was $822.5 million, or $3.49 per share, an increase of 71% compared with net income of $479 million, or $2.02 per share, in the first quarter of 2014.

“In the first quarter, we continued to gain share in the MS market and we believe that our MS product portfolio is well positioned to provide patients the breadth of choices that they need,” said in a statement CEO George A. Scangos, Ph.D. “While we saw moderating patient growth of our oral MS therapy TECFIDERA in the U.S. and Germany, the launch of PLEGRIDY continued to go well, and we have seen continued strong performance from TYSABRI. We believe that our portfolio offers patients leading choices among oral, interferon, and high-efficacy therapies, and we look forward to continued growth in our global market share.”

Profitability-wise, BIIB has a t-12 profit and operating margin of 30.25% and 40.90%, respectively. The $100.95 billion market cap company reported $3.5 billion in cash in its most recent quarter.

The biotechnology company currently prints a one year return of 40.27% and a year-to-date return of 26.76%.

The stock is currently down $13.73 to $416.55 on 52K shares.

Shares of ImmunoGen, Inc. (IMGN) lost 2.54% to $9.99 after the company released its earnings results on Friday. The firm reported Q3’15 EPS of ($0.25) per share vs. ($0.23) consensus on $11.4 million in revenue, up 65.2% from a year ago. The drug developer reported a loss of $21.6 million, or $0.25 per share, compared to a net loss of $37.5 million, or $0.44 per share, for the same quarter last year.

For its fiscal year ending June 30, 2015, IMGN’s net loss projection remains unchanged, and expected to be between $60 million and $65 million. Expected revenues are now estimated to be between $85 million and $95 million, compared with previous guidance of between $100 million and $105 million.

The $882.61 million market cap company reported $111.8 million in cash and cash equivalents as of March 31, 2015, compared with $142.3 million as of June 30, 2014.

IMGN currently prints a one year loss of 26.26% and a year-to-date return of around 68%.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.